|Articles|June 1, 2000

June 2000
Volume 6
Issue 6

The Economic Burden of Congestive Heart Failure in a Managed Care Population

Author(s)Jianwei Xuan, PhD, Phong T. Duong, PharmD, Patricia A. Russo, PhD

Download PDF: The Economic Burden of Congestive Heart Failure in a Managed Care Population

Articles in this issue

about 26 years ago

Article

Application of HEDIS Measures within a Veterans Affairs Medical Center

about 26 years ago

Article

Patient Desire and Reasons for Specialist Referral in a Gatekeeper-Model Managed Care Plan

about 26 years ago

Article

The Clinical and Economic Burden of Obesity in a Managed Care Setting

about 26 years ago

Article

HEDIS Measurement Moves Outside the Managed Care Box

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Readability of Hospital Patient Financial Policy Documents

BySamantha Randall, BA,Sumedha Raghu, MS,Ella Cho,Nina Linh Nguyen, MHA,Erin Trish, PhD,Erin L. Duffy, PhD, MPH

July 7th 2026

The Economic Burden of Congestive Heart Failure in a Managed Care Population

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

Upcoming 2026 FDA Decisions Could Expand Treatment Options Across Oncology and Hepatitis B

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

The Economic Burden of Congestive Heart Failure in a Managed Care Population

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

Upcoming 2026 FDA Decisions Could Expand Treatment Options Across Oncology and Hepatitis B

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer